|
|
||||||||||
|
J Am Coll Cardiol, 1984; 4:621-624 © 1984 by the American College of Cardiology Foundation |
N-Acetylprocainamide (NAPA), a class III antiarrhythmic drug, caused torsade de pointes in a 72 year old woman who had this arrhythmia on two previous occasions while being treated with quinidine and disopyramide. Initial evaluation with an intravenous infusion of NAPA indicated a favorable antiarrhythmic response. The QTC interval was prolonged, but the 2.4 ms/microgram per ml incremental QTC interval lengthening caused by NAPA was not greater than usual. During subsequent oral therapy with NAPA, torsade de pointes developed at plasma levels of this drug that appeared to be well tolerated during the initial evaluation.
This article has been cited by other articles:
![]() |
J.L. Bauman The role of pharmacokinetics, drug interactions and pharmacogenetics in the acquired long QT syndrome Eur. Heart J. Suppl., September 1, 2001; 3(suppl_K): K93 - K100. [Abstract] [PDF] |
||||
![]() |
L. Eckardt, W. Haverkamp, M. Borggrefe, and G. Breithardt Experimental models of torsade de pointes Cardiovasc Res, July 1, 1998; 39(1): 178 - 193. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |